Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ellman International Inc.

Latest From Orphagen Pharmaceuticals Inc.

Deals Of The Week: Busy ROR Gamma T Space Offers Small Molecule Promise In Autoimmune Disorders

Amgen’s July 31 deal with Japan’s Teijin marks at least the six partnerships around RORγt inhibitor compounds since 2009, with one more such deal likely this year. Plus news from a busy deal-making week, including tie-ups for AstraZeneca and Fibrogen, Actelion and Ceptaris, and Bristol and Samsung.

BioPharmaceutical Deals

Orphagen Pharmaceuticals Inc.

Orphagen Pharmaceuticals makes screening for orphan nucelar receptors, which have a notoriously low hit-rate and high rate of false positives, more efficient. It is currently screening for cholesterol-lowering drugs; an oral drug to suppress male hormones, for treating early-stage metastatic prostate cancer; and compounds to modulate the immune system, to treat HIV/AIDS and inflammatory or auto-immune diseases.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Medical Devices
    • Radiofrequency Devices
  • Therapeutic Areas
  • Dental & Oral Products
  • Dermatology
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Ellman International Inc.
  • Senior Management
  • Frank D'Amelio, CEO
    Michael Kucza, CFO
    Dave Pfeiffer, EVP, Chief Commercial Officer
  • Contact Info
  • Ellman International Inc.
    Phone: (800) 835-5355
    3333 Royal Ave.
    Oceanside, NY 11572